Intech Investment Management LLC Invests $195,000 in Liquidia Co. (NASDAQ:LQDA)

Intech Investment Management LLC acquired a new stake in Liquidia Co. (NASDAQ:LQDA) in the 3rd quarter, Holdings Channel.com reports. The firm acquired 19,544 shares of the company’s stock, valued at approximately $195,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Valmark Advisers Inc. acquired a new stake in shares of Liquidia in the 3rd quarter worth approximately $174,000. Clear Harbor Asset Management LLC acquired a new stake in Liquidia in the third quarter valued at $100,000. Ballentine Partners LLC purchased a new position in shares of Liquidia in the third quarter valued at $110,000. Signaturefd LLC raised its stake in shares of Liquidia by 38,400.0% during the 3rd quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock worth $100,000 after buying an additional 9,984 shares during the last quarter. Finally, DMC Group LLC boosted its position in shares of Liquidia by 36.7% in the 3rd quarter. DMC Group LLC now owns 13,883 shares of the company’s stock worth $139,000 after buying an additional 3,725 shares in the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on LQDA shares. BTIG Research dropped their price objective on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating for the company in a research note on Monday, August 19th. Scotiabank started coverage on Liquidia in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 price target for the company. Lifesci Capital assumed coverage on Liquidia in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price objective on the stock. Raymond James raised Liquidia from an “outperform” rating to a “strong-buy” rating in a research note on Monday, August 19th. Finally, HC Wainwright restated a “buy” rating and issued a $29.00 target price on shares of Liquidia in a report on Thursday, November 14th. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Liquidia presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

Liquidia Trading Down 4.1 %

Shares of NASDAQ:LQDA opened at $11.01 on Friday. The firm has a market cap of $931.89 million, a price-to-earnings ratio of -6.75 and a beta of 0.22. The stock’s 50-day moving average price is $10.84 and its two-hundred day moving average price is $11.31. Liquidia Co. has a 12-month low of $6.86 and a 12-month high of $16.99.

Insider Transactions at Liquidia

In other news, insider Rajeev Saggar sold 2,260 shares of the business’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $25,108.60. Following the completion of the sale, the insider now directly owns 207,383 shares of the company’s stock, valued at $2,304,025.13. The trade was a 1.08 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Roger Jeffs sold 8,053 shares of the stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $89,468.83. Following the completion of the transaction, the chief executive officer now directly owns 812,193 shares in the company, valued at $9,023,464.23. This trade represents a 0.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 22,007 shares of company stock worth $245,780 in the last three months. Company insiders own 30.10% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).